Genetic Testing

Diagnosing Li-Fraumeni syndrome soon after a patient's first cancer can reduce their overall cancer burden with an improved, personalized plan.  Faster identification enables earlier screening, proactive prevention, and better-informed treatment choices that minimize the risk of therapy-induced secondary cancers in women.  Read more on the research published in Clinical Breast Cancer (June 2026) by our

Our friends at MD Anderson have published the results from their prospective study validating a new, user-friendly method in determining if genetic testing should be pursued, referred to as LFSPRO.  Developed to assist genetic counselors, LFSPRO is a statistical tool that analyzes a patient's full family history to estimate the likelihood of a TP53 mutation.